Effects of antidepressants on glucose metabolism and diabetes mellitus type 2 in adults

Current Opinion in Psychiatry

Volumn 26, Issue 1, 2013, Pages 60-65

  Deuschle, Michael ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

Antidepressants; Depression; Diabetes mellitus type 2; Metabolic risks

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; FLUOXETINE; IMIPRAMINE; MAPROTILINE; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CARDIOMETABOLIC RISK; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DIABETIC NEUROPATHY; DISEASE SEVERITY; DRUG EFFECT; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEALTH BEHAVIOR; HUMAN; HYPOGLYCEMIA; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; PROGNOSIS; PSYCHOTHERAPY; REVIEW; SEXUAL FUNCTION; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS; BLOOD GLUCOSE; DEPRESSIVE DISORDER; DIABETES MELLITUS, TYPE 2; GLUCOSE; GLUCOSE METABOLISM DISORDERS; HUMANS; INSULIN RESISTANCE;

EID: 84870870025     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0b013e32835a4206     Document Type: Review

References (62)

1. Pan A, Lucas M, Sun Q, et al. Bidirectional association between depression and type 2 diabetes mellitus in women. Arch Intern Med 2010; 170:1884-1891.
2. Knol MJ, TwiskJWR, Beekman AT, et al. Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia 2006; 49:837-845.
3. Shehatah A, Rabie MA, Al-Shahry A. Prevalence and correlates of depressive disorders in elderly with type 2 diabetes in primary healthcare settings. J Affect Disord 2010; 123:197-201.
4. Ivanova A, Nitka D, Schmitz N. Epidemiology of antidepressant medication use in the Canadian diabetes population. Soc Psychiatry Psychiatr Epidemiol 2010; 45:911-919.
5. Pan A, Lucas M, Sun Q, et al. Increased mortality risk in women with depression and diabetes mellitus. Arch Gen Psychiatry 2012; 68:42-50.
6. Katon WJ. Epidemiology and treatment of depression in patients with chronic medical illness. Dialogues Clin Neurosci 2011; 13:7-23.
7. Himmerich H, Fulda S, Schaaf L, et al. Changes in weight and glucose tolerance during treatment with mirtazapine. Diabetes Care 2006; 29:170.
8. Weber-Hamann B, Gilles M, Lederbogen F, et al. Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. J Clinical Psychiatry 2006; 67:1856-1861.
9. Weber-Hamann B, Gilles M, Schilling C, et al. Improved insulin sensitivity in 51 nondiabetic depressed inpatients remitting during antidepressive treatment with mirtazapine and venlafaxine. J Clin Psychopharmacol 2008; 28:581-584.
10. Moosa MYH, Panz VR, Jeenah FY, Joffe BI. African women with depression: the effect of imipramine and fluoxetine on body mass index and leptin secretion. J Clin Psychopharmacol 2003; 23:549-552.
11. Ghaeli P, Shahsavand E, Mesbahi M, et al. Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder. J Clin Psychopharmacol 2004; 24:386-388.
12. Chen Y-C, Lin W-W, Chen Y-J, et al. Antidepressant effects on insulin sensitivity and proinflammatory cytokines in the depressed males. Mediators Inflamm 2010; 2010:573594.
13. LaimerM, Kramer-Reinstadler K, Rauchenzauner M, et al. Effect of mirtazapine treatment on body composition and metabolism. J Clin Psychiatry 2006; 67:421-424.
14. Kauffman RP, Castracane VD, White DL, et al. Impact of the selective serotonin reuptake inhibitor citalopram on insulin sensitivity, leptin and basal cortisol secretion in depressed and nondepressed euglycemic women of reproductive age. Gynecol Endocrinol 2005; 21:129-137.
15. Chen Y-C, Shen Y-C, Hung Y-J, et al. Comparisons of glucose-insulin homeostasis following maprotiline and fluoxetine treatment in depressed males. J Affect Disord 2007; 103:257-261.
16. PinarM, Gulsun M, Tasci I, et al. Maprotiline induced weight gain in depressive disorder: changes in circulating ghrelin and adiponectin levels and insulin sensitivity. Prog Neuro-Psychopharmacol Biol Psychiatry 2008; 32:135-139.
17. McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Exp Opin Drug Safety 2006; 5:157-168.
18. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010; 71:1259-1272.
19. Knol MJ, Geerlings MI, Egberts AC, et al. No increased incidence of diabetes in antidepressant users. Int Clin Psychopharmacol 2007; 22:382-386.
20. Kivimäki M, Tabak AG, Hamer M, et al. Antidepressant medication use, weight gain, and risk of type 2 diabetes. Diabetes Care 2010; 33:2611-2616.
21. Rubin RR, Ma Y, Marrero DG, et al. Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care 2008; 31:420-426.
22. Andersohn F, Schade R, Suissa S, Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009; 166:591-598.
23. Raeder MB, Bjelland I, Emil Vollset S, Steen VM. Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the Hordaland Health Study. J Clin Psychiatry 2006; 67:1974-1982.
24. Derijks HJ, Meyboom RHB, Heerdink ER, et al. The association between antidepressant use and disturbances in glucose homeostasis: evidence from spontaneous reports. Eur J Clin Pharmacol 2008; 64:531-538.
25. Brown LC, Majumdar SR, Johnson JA. Type of antidepressant therapy and risk of type 2 diabetes in people with depression. Diabetes Res Clin Pract 2008; 79:61-67.
26. van Reedt Dortland A, Giltay E, van Veen T, et al. Metabolic syndrome abnormalities are associated with severity of anxiety and depression and with tricyclic antidepressant use. Acta Psychiatr Scand 2010; 122:30-39.
27. Rubin RR, Gaussoin SA, Peyrot M, et al. Cardiovascular disease risk factors, depression symptoms and antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes. Diabetologia 2010; 53:1581-1589.
28. Ma Y, Balasubramanian R, Pagoto SL, et al. Elevated depressive symptoms, antidepressant use, and diabetes in a large multiethnic national sample of postmenopausal women. Diabetes Care 2011; 34:2545-2547.
29. Knol MJ, Geerlings MI, Grobbee DE, et al. Antidepressant use before and after initiation of diabetes mellitus treatment. Diabetologia 2009; 52:425-432.
30. Weber-Hamann B, Kopf D, Lederbogen F, et al. Activity of the hypothalamuspituitary- adrenal system and oral glucose tolerance in depressed patients. Neuroendocrinology 2005; 81:200-204.
31. Pyykkönen A-J, Räikkönen K, Tuomi T, et al. Depressive symptoms, antidepressant medication use, and insulin resistance: the PPP-Botnia Study. Diabetes Care 2011; 34:2545-2547.
32. Wilkins TL, Sambamoorthi U. Antidepressant use, depression, lifestyle factors, and new-onset diabetes. Int Clin Psychopharmacol 2011; 26: 159-168.
33. Kivimäki M, Batty GD, Jokela M, et al. Antidepressant medication use and risk of hyperglycemia and diabetes mellitus: a noncausal association? Biol Psychiatry 2011; 70:978-984.
34. Atlantis E, Browning C, Sims J, Kendig H. Diabetes incidence associated with depression and antidepressants in the Melbourne Longitudinal Studies on Healthy Ageing (MELSHA). Int J Geriatric Psychiatry 2010; 25:688-696.
35. Lustman PJ, Freedland KE, Griffith LS, Clouse RE. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care 2000; 618-623.
36. Maheux P, Ducros F, Bourque J, et al. Fluoxetine improves insulin sensitivity in obese patients with noninsulin-dependent diabetes mellitus independently of weight loss. Int J Obes Relat Metab Disord 1997; 21:97-102.
37. Daubresse JC, Kolanowski J, Krzentowski G, et al. Usefulness of fluoxetine in obese noninsulin-dependent diabetics: a multicenter study. Obes Res 1996; 4:391-396.
38. Breum L, Bjerre U, Bak JF, et al. Long-term effects of fluoxetine on glycemic control in obese patients with noninsulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity. Metabolism 1995; 44:1570-1576.
39. Connolly VM, Gallagher A, Kesson CM. A study of fluoxetine in obese elderly patients with type 2 diabetes. Diabetes Med 1995; 12:416-418.
40. O'Kane M, Wiles PG, Wales JK. Fluoxetine in the treatment of obese type 2 diabetic patients. Diabet Med 1994; 11:105-110.
41. Gray DS, Fujioka K, Devine W, Bray GA. Fluoxetine treatment of the obese diabetic. Int J Obes Relat Metab Disord 1992; 16:193-198.
42. Kutnowski M, Daubresse JC, Friedman H, et al. Fluoxetine therapy in obese diabetic and glucose intolerant patients. Int J Obes Relat Metab Disord 1992; 16(Suppl 4):S63-S66.
43. Potter van Loon BJ, Radder JK, Frölich M, et al. Fluoxetine increases insulin action in obese type II (noninsulin dependent) diabetic patients. Int J Obes Relat Metab Disord 1992; 16(suppl 4):S55-S61.
44. Lustman PJ, Griffith LS, Clouse RAYE, Kenneth E. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom Med 1997; 250:241-250.
45. Lustman PJ, Griffith LS, Freedland KE, et al. Cognitive behavior therapy for depression in type 2 diabetes mellitus. Ann Intern Med 1998; 129:613-621.
46. van der Feltz-Cornelis CM, Nuyen J, Stoop C, et al. Effect of interventions for major depressive disorder and significant depressive symptoms in patients with diabetes mellitus: a systematic review and meta-analysis. Gen Hosp Psychiatry 2010; 32:380-395.
47. Katon W, Unützer J, Fan MY, et al. Cost-effectiveness and net benefit of enhanced treatment of depression for older adults with diabetes and depression. Diabetes Care 2006; 29:265-270.
48. Kinder LS, Katon WJ, Ludman E, et al. Improving depression care in patients with diabetes and multiple complications. J Gen Intern Med 2006; 21:1036-1041.
49. Anderson RJ, Gott BM, Sayuk GS, et al. Antidepressant pharmacotherapy in adults with type 2 diabetes rates and predictors of initial response. Diabetes Care 2010; 33:485-489.
50. Lustman PJ, Clouse RE, Nix BD, et al. Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 2006; 63:521-529.
51. Ye Z, Chen L, Yang Z, et al. Metabolic effects of fluoxetine in adults with type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. PloS One 2011; 6:e21551.
52. Goodnick PJ, Kumar A, Henry JH, et al. Sertraline in coexisting major depression and diabetes mellitus. Psychopharmacol Bull 1997; 33:261-264.
53. Paile-Hyvärinen M, Wahlbeck K, Eriksson JG. Quality of life and metabolic status in mildly depressed patients with type 2 diabetes treated with paroxetine: a double-blind randomised placebo controlled 6-month trial. BMC Fam Pract 2007; 8:34.
54. Lustman PJ, Williams MM, Sayuk GS, et al. Factors influencing glycemic control in type 2 diabetes during acute- and maintenance-phase treatment of major depressive disorder with bupropion. Diabetes Care 2007; 30:459-466.
55. Lin EH, Von Korff M, Ciechanowski P, et al. Treatment adjustment and medication adherence for complex patients with diabetes, heart disease, and depression: a randomized controlled trial. Ann Fam Med 2012; 10:6-14.
56. Knol MJ, Derijks HJ, Geerlings MI, et al. Influence of antidepressants on glycaemic control in patients with diabetes mellitus. Pharmacoepidemiol Drug Saf 2008; 17:577-586.
57. Derijks HJ, Heerdink ER, De Koning FH, et al. The association between antidepressant use and hypoglycaemia in diabetic patients: a nested casecontrol study. Pharmacoepidemiol Drug Saf 2008; 17:336-344.
58. Sayuk GS, Gott BM, Nix BD, Lustman PJ. Improvement in sexual functioning in patients with type 2 diabetes and depression treated with bupropion. Diabetes Care 2011; 34:332-334.
59. Wasan AD, Ossanna MJ, Raskin J, et al. Safety and efficacy of duloxetine in the treatment of diabetic peripheral neuropathic pain in older patients. Curr Drug Saf 2009; 4:22-29.
60. Kadiroglu AK, Sit D, Kayabasi H, et al. The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus. J Diabetes Complications 2008; 22:241-245.
61. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005; 116:109-118.
62. Hardy T, Sachson R, Shen S, et al. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care 2007; 30:21-26.